Drug intelligence / Profile preview

bulumtatug fuvedotin

Development stage: Phase 3
Lead developer: Mabwell
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Bulumtatug fuvedotin is an investigational antibody-drug conjugate (ADC) developed by Mabwell Biotech. It targets both tubulin and nectin-4, utilizing a monoclonal antibody linked to a cytotoxic payload via a cleavable linker. The mechanism of action involves inhibition of tubulin polymerization, leading to cell cycle arrest and apoptosis in target cells expressing nectin-4. This dual-targeting ADC is being developed primarily for oncology indications[6].

Other names: bulumtatug fuvedotin

Targets

TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on bulumtatug fuvedotin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bulumtatug fuvedotin.

Explore the full profile